GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated September 21, 2023, serves as a transaction notification for the month of September 2023. The document discloses share purchases made by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. It does not contain financial performance results, operational updates, or strategic commentary.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transaction prices and volumes for individual directors.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records compliance disclosures regarding insider trading activity.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, risk factors, contingencies, or discussion of unusual items.
Transaction Details
On September 20, 2023, the following PDMRs purchased GSK securities:
- Sir Jonathan Symonds (Non-Executive Chair): Purchased 1,900 Ordinary Shares at £15.2600 on the London Stock Exchange.
- Urs Rohner (Independent Non-Executive Director): Purchased 453 Ordinary Shares at £15.2880 on the London Stock Exchange.
- Charles Bancroft (Senior Independent Non-Executive Director): Purchased 1,691 ADSs at $38.0255 on the New York Stock Exchange.
- Dr. Hal Barron (Non-Executive Director): Purchased 219 ADSs at $38.0255 on the New York Stock Exchange.
- Dr. Anne Beal (Independent Non-Executive Director): Purchased 220 ADSs at $38.0255 on the New York Stock Exchange.
- Dr. Harry Dietz (Independent Non-Executive Director): Purchased 220 ADSs at $38.0255 on the New York Stock Exchange.
- Dr. Jesse Goodman (Independent Non-Executive Director): Purchased 220 ADSs at $38.0255 on the New York Stock Exchange.
- Elizabeth McKee Anderson (Independent Non-Executive Director): Purchased 219 ADSs at $38.0255 on the New York Stock Exchange.
- Dr. Vishal Sikka (Independent Non-Executive Director): Purchased 790 ADSs at $38.0255 on the New York Stock Exchange.
Investor Verification Checklist
- Verify the total aggregate volume of shares purchased by the board on September 20, 2023.
- Confirm the exchange rates used to compare the GBP and USD transaction prices if analyzing total value.
- Check subsequent filings to determine if these purchases were part of a broader share buyback program or individual director retention plans.
- Note that this filing provides no data on GSK's quarterly or annual financial performance.